Added to YB: 2026-06-18
Pitch date: 2026-06-16
BNTX [neutral]
BioNTech SE
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Market Cap
$19.5B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.31
P/E
-15.09
EV/Sales
2.18
Sector
Biotechnology
Category
growth
Show full summary:
BioNTech SE (BNTX US): Investment case now supported by several late‑stage assets in oncology
BNTX (update): ASCO 2026 data for pumitamig (PD-(L)1 x VEGF bispecific) strong: 63.6% confirmed response in non-sq NSCLC, 72.7% sq, 47.6% in PD-L1 negatives. Wide oncology pipeline (ADCs, mRNA, immunomodulators) enabling proprietary combos; H2'26 readouts key. €16.8bn cash funds pivotal trials.
Read full article (2 min)